Concordia International Corp. (NASDAQ: CXRX) is one of 112 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Concordia International Corp. to related businesses based on the strength of its dividends, profitability, valuation, earnings, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Concordia International Corp. and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Concordia International Corp. -269.97% -83.96% -0.62%
Concordia International Corp. Competitors -3,613.41% -52.33% -8.32%

Valuation and Earnings

This table compares Concordia International Corp. and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Concordia International Corp. $677.25 million $326.58 million -0.04
Concordia International Corp. Competitors $7.86 billion $2.50 billion 1.27

Concordia International Corp.’s competitors have higher revenue and earnings than Concordia International Corp.. Concordia International Corp. is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Concordia International Corp. has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Concordia International Corp.’s competitors have a beta of 0.86, indicating that their average share price is 14% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Concordia International Corp. and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Concordia International Corp. 5 1 0 0 1.17
Concordia International Corp. Competitors 943 3779 5990 164 2.49

Concordia International Corp. currently has a consensus price target of $8.00, suggesting a potential upside of 529.92%. As a group, “Pharmaceuticals” companies have a potential upside of 26.64%. Given Concordia International Corp.’s higher probable upside, analysts plainly believe Concordia International Corp. is more favorable than its competitors.

Insider & Institutional Ownership

9.1% of Concordia International Corp. shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 12.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Concordia International Corp. competitors beat Concordia International Corp. on 9 of the 12 factors compared.

About Concordia International Corp.

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Stock Ratings for Concordia International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International Corp. and related stocks with our FREE daily email newsletter.